Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (258)	2/10/1999 1:01:00 AM
From: Miljenko Zuanic	Respond to of 804

V1: <<Obviously the key is off label use.>> I guess so. For now oncology is main field. But, anti-inflammatory results may surprise many, more optimistic view. <One of the drivers will be when clinical results are released and published for off label indications. >> I will formulate this bit differently. Clinical results are already known and are positive and very encourage (Crohn's, MM, brain tumor, even prostate and breast cancer,...any solid tumor,.. wasting,..). So, it will be up to physicians confidence (related to unwonted effects) to prescribe T without strong fear that something may go wrong. Also there are (unfortunately) plenty of male pts who may benefit from T. <<Do you know when the company is planning on releasing clinical trial results.>> Some trials are conduced by CELG, some are only sponsored by CELG. Exactly presentation do not know, but here are some idea (only idea ): Crohn's: trial completed, May Crohn's conf. in Florida or any IBD conference, Brain Cancer: trial completed, angiogenesis conf. in Meryland (2-1999), or ASCO in Atlanta (May) Prostate cancer: ongoing, interim analysis at next Prostate cancer conf. Brest cancer: preliminary data at ASCO Hope this help. Miljenko